Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
Appointed director
|
|
ARGOS THERAPEUTICS INC (ARGS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/03/2019 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits |
| 02/14/2019 |
SC 13D/A
| ForArgos B.V. reports a 2.9% stake in ARGOS THERAPEUTICS INC. |
| 12/03/2018 |
8-K
| Resignation/termination of a director |
| 11/19/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/14/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/20/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 08/15/2018 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/20/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/19/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/15/2018 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/15/2018 |
10-Q
| Quarterly Report for the period ended March 31, 2018 |
| 05/09/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
| 04/27/2018 |
GN
| Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth |
| 04/24/2018 |
8-K
| Quarterly results |
| 04/19/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 04/02/2018 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 04/02/2018 |
10-K
| Annual Report for the period ended December 31, 2017 |
| 04/02/2018 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits|
Docs:
|
"Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights DURHAM, NC, April 02, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today reported financial results and operational highlights for the fourth quarter and full year 2017. Jeff Abbey, CEO of Argos Therapeutics, stated, "Although we faced a very challenging 2017, we have been able to continue the Phase 3 ADAPT clinical trial of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and look forward to the next interim data analysis, which we expect to occur during the second quarter of 2018. In addition to cont..." |
|
| 04/02/2018 |
GN
| Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights |
| 03/28/2018 |
GN
| Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018 |
| 03/07/2018 |
8-K
| Other Events |
| 03/01/2018 |
GN
| Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape |
| 02/16/2018 |
8-K
| Quarterly results |
| 02/15/2018 |
GN
| Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy |
| 02/14/2018 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 02/05/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Amended and Restated Sales Agreement, by and between the Company and Cowen and Company, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb. 05, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has entered into an option agreement with Pharmstandard International, S.A. and Actigen Limited under which the Company has an option to license a group of fully human anti-PD1 monoclonal antibodies and related technology. Results of a preclinic..." |
|
| 02/02/2018 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 01/30/2018 |
8-K/A
| Financial Statements and Exhibits |
| 01/25/2018 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/18/2018 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 01/18/2018 |
GN
| Argos Announces One-for-Twenty Reverse Stock Split |
| 01/08/2018 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"Argos Announces $1.5 Million Equity Investment by Lummy , Ltd. DURHAM, N.C., Jan. 08, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has signed a stock purchase agreement with Lummy , Ltd. , the Company’s partner for Rocapuldencel-T in China and certain other territories, under which the Company has agreed to issue and sell to Lummy in a private financing 7.5 million shares of the Company’s common stock for an aggregate purchase price of $1.5 million. The sale of the shares is expected to close on or prior to March 7, 2018. Lummy has agreed that, on the closing date, it will execute and deliver a lockup a..." |
|
| 01/08/2018 |
GN
| Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd. |
| 01/04/2018 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|
|
|